| Literature DB >> 32793665 |
Jiahui Zhang1,2, Xiaoli Wang1, Lixia Zhang1, Linpeng Yao1, Xing Xue1, Siying Zhang1, Xin Li3, Yuanjun Chen3, Peipei Pang3, Dongdong Sun4, Juan Xu4, Yanjun Shi5, Feng Chen1.
Abstract
BACKGROUND: Radiomics can be used to determine the prognosis of liver cancer, but it might vary among cancer types. This study aimed to explore the clinicopathological features, radiomics, and survival of patients with hepatocellular carcinoma (HCC), mass-type cholangiocarcinoma (MCC), and combined hepatocellular-cholangiocarcinoma (CHCC).Entities:
Keywords: Hepatocellular carcinoma (HCC); cholangiocarcinoma; magnetic resonance imaging (MRI); postoperative survival; radiomics
Year: 2020 PMID: 32793665 PMCID: PMC7396247 DOI: 10.21037/atm-19-4668
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure S1Extraction process of the morphological features. (A) Magnetic resonance enhanced equilibrium phase image; (B) manual delineation of the tumor; (C) three-dimensional segmentation of the lesion. Obtaining the quantitative parameter characteristics.
Clinicopathological features of the patients with primary hepatic carcinoma
| Variables | MCC (n=44) | HCC (n=59) | CHCC (n=33) | P |
|---|---|---|---|---|
| Gender, male (%) | 26 (59.1%)a | 50 (84.7%)b | 21 (63.6%)ab | 0.009 |
| Age (years) | 58.4±9.8 | 58.2±11.2 | 54.4±11.3 | 0.202 |
| >55 years | 29 (65.9%) | 36 (61.0%) | 18 (54.5%) | 0.605 |
| Tumor number | 0.130 | |||
| 1 | 43 (97.7%) | 59 (100%) | 31 (93.9%) | |
| 2 | 1 (2.3%) | 0 | 1 (3.0%) | |
| 3 | 0 | 0 | 1 (3.0%) | |
| Macrovascular invasion | 9 (20.5%) | 8 (13.6%) | 1 (3%) | 0.083 |
| Lymphadenopathy* | 18 (40.9%)a | 10 (16.9%)b | 13 (39.4%)ab | 0.013 |
| Tumor size (cm) | 5.56±2.59a | 6.09±2.44a | 4.06±1.89b | 0.001 |
| Tumor size >3 cm | 35 (79.5%)a | 58 (98.3%)b | 23 (69.7%)a | <0.001 |
| HBsAg positive | 19 (43.2%)a | 44 (74.6%)b | 27 (81.8%)b | <0.001 |
| CA19-9 (U/mL) | 420.83±1,073.48a | 24.36±42.78b | 42.67±63.68b | 0.003 |
| CA19-9 >37 U/mL | 14 (31.8%)a | 2 (3.4%)b | 6 (18.2%)ab | <0.001 |
| CA125 (U/mL) | 153.6±736.66 | 14.87±16.17 | 19.66±33.61 | 0.208 |
| CA125 >35 U/mL | 8 (18.2%)a | 2 (3.4%)b | 2 (6.1%)ab | 0.026 |
| Ferritin (ng/mL) | 210.55±160.98 | 295.97±369.52 | 229.78±159.2 | 0.252 |
| Ferritin >323 ng/mL | 8 (18.2%) | 14 (23.7%) | 9 (27.3%) | 0.631 |
| AFP (ng/mL) | 8.59±25.72 | 2,399.39±8,286.27 | 290.62±644.95 | 0.059 |
| AFP >20 ng/mL | 2 (4.5%)a | 29 (49.2%)b | 20 (60.6%)b | <0.001 |
| CEA (ng/mL) | 3.70±4.99 | 2.41±1.33 | 2.57±1.58 | 0.090 |
| CEA >5 ng/mL | 6 (13.6%) | 3 (5.1%) | 3 (9.1%) | 0.322 |
*, lymphadenopathy was assessed by magnetic resonance imaging; a,b, different letters indicate statistically significant differences. HCC, hepatocellular carcinoma; MCC, mass-type cholangiocarcinoma; CHCC, combined hepatocellular-cholangiocarcinoma; AFP, α-fetoprotein; HBsAg, hepatitis surface antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen.
Figure S2Elastic network dimension reduction diagram. The elastic network method was used to reduce the image feature parameters of the (A) diffusion weighted imaging (DWI), (B) enhanced equilibrium (EP), and (C) DWI and EP. The 5-fold cross validation method was used to determine the optimized lambda (λ). The optimized λ was 0.04608123, 0.06285455, and 0.06285455 [ln(λ): −3.077349, −2.766932, and −2.766932] and the number of features corresponding to the value is five, five, and seven, respectively.
Figure 1Kaplan-Meier curves of overall survival of mass-type cholangiocarcinoma (MCC) (n=44), hepatocellular carcinoma (HCC) (n=59), and combined hepatocellular-cholangiocarcinoma (CHCC) (n=33). The three groups of different types of primary liver cancer patients had significant differences in survival (P=0.02). There was a significant difference between the HCC and CHCC groups (P=0.005).
Elastic net and multivariable Cox model analysis of OS for primary hepatic carcinomas using a combination of clinicopathological features and texture parameters derived from MR-DWI
| Variables | Overall survival | |
|---|---|---|
| HR (95% CI) | P | |
| Macrovascular invasion* | 0.296 (0.099–0.882) | 0.029 |
| The largest tumor diameter ≤3 cm* | 1.413 (1.150–1.736) | <0.001 |
| Ferritin >323 ng/mL | 2.484 (1.073–5.751) | 0.034 |
| AFP >20 ng/mL | 2.005 (1.017–3.951) | 0.045 |
| CEA >5 ng/mL | 5.372 (1.871–15.423) | 0.002 |
| Correlation_angle90_offset1 | 0.198 (0.071–0.553) | 0.002 |
| Inverse Difference Moment_AllDirection_offset4 | 1.501 (1.061–2.124) | 0.022 |
| Cluster Prominence_angle0_offset7 | 0.183 (0.071–0.471) | 0.001 |
*, macrovascular invasion, tumor size, and lymphadenopathy were assessed by magnetic resonance imaging. AFP, α-fetoprotein; HBsAg, hepatitis surface antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio.
Elastic net and multivariable Cox model analysis of OS for primary hepatic carcinomas using a combination of clinicopathological features and texture parameters derived from MR-EP
| Variables | Overall survival | |
|---|---|---|
| HR (95% CI) | P | |
| Gender, male | 0.394 (0.175–0.889) | 0.025 |
| Lymphadenopathy* | 2.197 (1.074–4.494) | 0.031 |
| Ferritin >323 ng/mL | 2.639 (1.210–5.753) | 0.015 |
| AFP >20 ng/mL | 2.351 (1.175–4.704) | 0.016 |
| CEA >5 ng/mL | 2.885 (1.066–7.809) | 0.037 |
| Max intensity | 1.044 (0.723–1.506) | 0.818 |
| Uniformity | 0.453 (0.276–0.745) | 0.002 |
| Cluster Prominence_angle135_offset7 | 0.544 (0.331–0.895) | 0.017 |
*, used to mark the corresponding variables were evaluated by magnetic resonance imaging. AFP, α-fetoprotein; HBsAg, hepatitis surface antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio.
Elastic net and multivariable Cox model analysis of OS for primary hepatic carcinomas using a combination of clinicopathological features and texture parameters derived from MR-DWI and MR-EP
| Variables | Overall survival | |
|---|---|---|
| HR (95% CI) | P | |
| Gender, male | 0.375 (0.161–0.873) | 0.023 |
| Macrovascular invasion* | 0.297 (0.096–0.921) | 0.036 |
| Lymphadenopathy* | 2.337 (1.130–4.830) | 0.022 |
| AFP >20 ng/mL | 2.671 (1.348–5.293) | 0.005 |
| CEA >5 ng/mL | 4.112 (1.390–12.162) | 0.011 |
| Uniformity_EP | 0.420 (0.253–0.695) | <0.001 |
| GLCMEnergy_angle0_offset7_DWI | 1.550 (1.167–2.060) | 0.002 |
| ClusterProminence_angle135_offset7_EP | 0.562 (0.335–0.943) | 0.029 |
*, used to mark the corresponding variables were evaluated by magnetic resonance imaging. AFP, α-fetoprotein; HBsAg, hepatitis surface antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio.
Multivariable Cox model analysis of OS for primary hepatic carcinomas using clinicopathological features
| Variables | Overall survival | |
|---|---|---|
| HR (95% CI) | P | |
| Gender, male | 0.383 (0.177–0.828) | 0.015 |
| Lymphadenopathy* | 2.158 (1.090–4.273) | 0.027 |
| The largest tumor diameter ≤3 cm* | 1.328 (1.158–1.532) | <0.001 |
| Ferritin >323 ng/mL | 2.417 (1.134–5.153) | 0.022 |
| AFP >20 ng/mL | 3.045 (1.551–5.978) | 0.001 |
| CEA >5 ng/mL | 2.790 (1.059–7.355) | 0.038 |
*, used to mark the corresponding variables were evaluated by magnetic resonance imaging. AFP, α-fetoprotein; HBsAg, hepatitis surface antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio.
Figure 2Nomogram for predicting overall survival (OS) of patients who received liver resection for mass-type cholangiocarcinoma (MCC), hepatocellular carcinoma (HCC), and combined hepatocellular-cholangiocarcinoma (CHCC). (A) Clinicopathological features and texture parameters calculated from diffusion-weighted imaging (DWI), (B) clinicopathological features and texture parameters calculated from the equilibrium phase (EP); (C) clinicopathological features and texture parameters calculated from DWI and EP; (D) clinicopathological features only. AFP, α-fetoprotein; CEA, carcinoembryonic antigen.
Figure 3Analysis of imaging features and clinical and pathological features by a decision curve nomogram. The red, green, blue and yellow lines represent the nomograms from models 1, 2, 3 and 4 respectively. The light gray line represents the hypothesis that all clinicopathological and imaging features are related to postoperative survival time. The dark gray line indicates that there is no hypothesis that all clinicopathological and imaging features are related to postoperative survival.